富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究*

doi:10.3969/j.issn.1672-5069.2024.05.026

Abstract

Abstract: Objective The aim of this study was to investigate intestinal barrier function index changes in patients with compensated hepatitis B liver cirrhosis (LC) and high serum viral loads undergoing tenofovir alafenamide fumarate (TAF) or entecavir (ETV) therapy. Methods 64 patients with compensated hepatitis B-induced LC and high serum viral loads (HBVDNAswere 1equal to or greater than×10⁶ IU/mL) were enrolled in our hospital between January 2020 and January 2023, and we randomly assigned them to receive TAF (observation, n=32) or to ETV (control, n=32) therapy. The regimen continued and antiviral efficacy was assessed by end of 12 months. Urine lactulose/mannitol (L/M) ratio was detected by high performance liquid chromatography. Serum D-lactic acid was measured by colorimetry, serum diamine oxidase (DAO) by ultraviolet colorimetry, and serum endotoxin and interleukin-7 (IL-7) levels was assayed by EIISA. Serum procalcitonin (PCT) level was determined by chemiluminescence immunoassay, and heparin-binding protein (HBP) level was detected by immunofluorescence quantitative method. Results By end of 12-month antiviral treatment, complete virological and biochemical responses were obtained in the two groups, and there were no significant differences as respect to serum bilirubin, ALT and AST levels in the two groups (P>0.05); serum DAO, D-lactic acid, endotoxin and urine L/M ratio in the observation group were (2.8±0.6)U/mL, (7.9±1.8)μg/mL, (0.5±0.1)EU/mL and (7.3±1.6)%, all not significantly different compared to [(3.0±0.5)U/mL, (7.8±2.2)μg/mL,(0.6±0.1)EU/mL and (8.1±1.9)%, respectively, P>0.05] in the control; serum PCT, HBP and IL-7 levels were (0.01±0.00)μg/L, (43.1±3.7)ng/mL and (768.9±20.3)pg/mL, also not significantly different as compared to [(0.02±0.01)μg/L,(47.6±3.2)ng/mL and (743.4±21.5)pg/mL, respectively, P>0.05] in the control groups. Conclusion Both TAF or ETV has a satisfactory antiviral efficacy in treatment of patients with compensated hepatitis B-induced LC, without intestinal barrier function damage.

Key words: Liver cirrhosis, Hepatitis B, Tenofovir alafenamide fumarate, Entecavir, High serum viral loads, Intestinal barrier functions, Therapy

Li Shuangling, Liu Li, Chen Yi, et al. Intestinal barrier function index changes in patients with compensated hepatitis B cirrhosis and high serum viral loads undergoing tenofovir alafenamide fumarate or entecavir therapy[J]. Journal of Practical Hepatology, 2024, 27(5): 749-752.

References

[1] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev, 2020, 33(2):e00046-19.
[2] Tseng TC, Liu CJ, Yang WT,et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther, 2021, 53(8):908-918.
[3] Tseng TC, Liu CJ, Hsu CY,et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology, 2019, 157(6):1518-1529,e3.
[4] Zhang T, Yang Y, Wang B,et al. Meta-analysis of influences of Biejiajian pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: protocol of systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(51):e18458.
[5] Han Z, Hou H. Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission ofHepatitis B virus. Aliment Pharmacol Ther, 2019, 50(6):707-708.
[6] Lau G, Yu ML, Wong G,et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int, 2021, 15(5):1031-1048.
[7] Ou H, Yuan D, Bi Y, et al. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis. Cell Commun Signal, 2021, 19(1):33.
[8] 黄俊榕,吴昌儒,吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究. 实用肝脏病杂志,2022,25(3):327-330.
[9] Liao Q, Wen J, Jiang K, et al. Kushenin combined with adefovir dipivoxil or entecavir for chronic Hepatitis B: asystematic review and Meta-Analysis. Evid Based Complement Alternat Med, 2021, 2021:8856319.
[10] 王帅,陈蕾,张宁,等.FGF-23基因多态性与乙型肝炎病毒感染孕妇应用富马酸丙酚替诺福韦阻断效果的关联.中华医院感染学杂志,2023,33(10):1545-1549.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[12] Liu Y, Guo W, Li M. Diammoniumglycyrrhizinate preparation for Liver function recovery in chronic hepatitis B in China: a Meta-analysis with trial sequential analysis. Curr Pharm Des, 2022, 28(25):2089-2112.
[13] Yuan J, Peng Y, Hao FB,et al. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY), 2021, 13(5):7147-7165.
[14] Choi WM, Yip TC, Wong GL,et al. Hepatocellular carcinoma risk in patients with chronic Hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis. J Hepatol, 2023, 78(3):534-542.
[15] Gharehbeglou M, Yazdani S, White K, et al. Atorvastatin rapidly reduces hepatitis B viral load in combination with tenofovir: aprospective clinical trial. Can J Infect Dis Med Microbiol, 2022 ,2022:3443813.
[16] Lim YS, Seto WK, Kurosaki M,et al. Review article: switching patients with chronic Hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther, 2022, 55(8):921-943.
[17] Li FC, Fan YC, Li YK,et al. Plasma diamine oxidase level predicts 6-month readmission for patients with Hepatitis B virus-related decompensated cirrhosis. Virol J, 2019, 16(1):115.
[18] 胡艳艳,叶晓云,俞巧燕.乙型肝炎肝硬化合并自发性细菌性腹膜炎PCT和HBP与IL-7表达水平.中华医院感染学杂志,2021,31(2):184-187.
[19] Agarwal K, Brunetto M, Seto WK,et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for Hepatitis B virus infection. J Hepatol, 2018, 68(4):672-681.
[20] Zheng W, Liang X, Shui L,et al. Serum procalcitonin correlates with renal function in Hepatitis B virus-related acute-on-chronic liver failure. Cell Physiol Biochem, 2018, 50(5):1794-1803.
[21] Hsu YC, Yeh ML, Wong GL, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic Hepatitis B. J Infect Dis, 2021, 224(11):1890-1899.

Intestinal barrier function index changes in patients with compensated hepatitis B cirrhosis and high serum viral loads undergoing tenofovir alafenamide fumarate or entecavir therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wei Xinhuan, Liu Yali, Zhang Jing, et al. Current landscape and future perspectives of metabolic-associated fatty liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 641-645.
[2]	Zhang Zhiqiang, Fang Jian, Li Dongliang. Strategy and challenges of interventional treatment in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2024, 27(5): 650-653.
[3]	Hepatology Group, Chronic Disease Management Branch, China Medicinal Biotechnology Association. Multidisciplinary expert consensus on prevention and treatment of inflammatory liver injury with bicyclol [J]. Journal of Practical Hepatology, 2024, 27(5): 659-668.
[4]	Peng Lin, Yang Chun, Li Xingquan. Peginterferon alpha and entecavir combination in treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(5): 677-680.
[5]	Ran Shurong, Liu Yang, Lei Lan. Risk factors of low-level viremia and rescue switch treatment to tenofovir alafenamide fumarate in entecavir-treated patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(5): 681-684.
[6]	Li Fang, Yang Hongfei, Zhang Qing. Virological response of patients with chronic hepatitis C to sofebuvir and redipavir combination regimen treatment [J]. Journal of Practical Hepatology, 2024, 27(5): 685-688.
[7]	Liu Yaguang, Hu Lianzhi, Dong Yixia, et al. Antiviral efficacy and serum interferon-γ and interleukin-10 level changes in patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2024, 27(5): 689-692.
[8]	Mo Weibin, Zhang Qingyou, Huang Xiaohan, et al. Antiviral efficacy of danoprevir and ravidasvir combination in treating patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2024, 27(5): 693-696.
[9]	Gao Yi, Shen Xiaoxue, Xia Suqin, et al. Bile acid composition and their impact of response to immunosuppressant or UCDA therapy in patients with autoimmune hepatitis and primary biliary cholangitis [J]. Journal of Practical Hepatology, 2024, 27(5): 709-712.
[10]	Jiang Yezhou, Hua Xia, Chen Guofei, et al. Changes of serum leptin level and percentages of peripheral blood regulatory T cells and Th17 cells in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(5): 713-716.
[11]	Zhu Jiarui, Ge Shaofeng, Ye Guiyun, et al. Implications of peripheral blood NLR and nCD64 index in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(5): 717-720.
[12]	Wang Xiujuan, Zhu He, Zhang Rumeng, et al. Different tapering prednisone dose in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(5): 729-732.
[13]	Xin Liangliang, Wen Zhi. Assessment of esophageal varices by 2D-SWE technology, FIB-4 and serum VEGF level in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2024, 27(5): 737-740.
[14]	Ruini, Wang Shasha, Jia Zebo, et al. Endoscopic variceal ligation with lauromacrogol and snake venom hemocoagulase injection in treating patients with hepatitis B liver cirrhosis complicated by esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2024, 27(5): 741-744.
[15]	Tian Lin, Kang Ying, Cui Jie, et al. Esophageal variceal ligation with auxiliary oral thrombin and intravenous octreotide administration in the treatment of cirrhotics with esophageal and gastric variceal bleeding [J]. Journal of Practical Hepatology, 2024, 27(5): 745-748.